MissionIR's  Instablog

Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
My blog:
MissionIR Blog
  • VistaGen Therapeutics, Inc. (VSTA) Addressing Costly, Far-Reach Neuropathic Pain Condition With Development Of Lead Candidate AV-101 0 comments
    Oct 31, 2013 2:55 PM | about stocks: VTGN

    Neuropathic pain is a serious and chronic condition that affects millions of people around the world. This pain follows damage or disease of the peripheral or nervous system, resulting in a variety of abnormal sensations such as the feeling of electric shock, burning or coldness, numbness and itching, or "pins and needles."

    Recent market research estimates that more than 1.5 billion people worldwide are afflicted with neuropathic pain, costing the U.S. public health system alone between $560 billion - $635 billion annually, according to the American Academy of Pain Medicine.

    Small-cap company VistaGen Therapeutics' lead small molecule drug candidate, AV-101, is being developed in the United States for the treatment of neuropathic pain. AV-101 is also being developed for additional indications, such as depression and other neurological indications.

    To-date, the company has been awarded more than $8.8 million from the National Institute of Health for the development of this treatment.

    In preclinical studies, AV-101 demonstrated positive levels of oral bioavailability, rapid and efficient transport across the blood-brain barrier, and preferential conversion into 7-CKYNA at the site of the patient's seizures and potential neural damage in the brain and spinal cord.

    So far the drug candidate has completed phase 1 development in the United States under and active Investigational New Drug (NYSE:IND) application with the U.S. Food and Drug Administration.

    VistaGen Therapeutics believes that safety results from the completed phase 1 program has the potential to position the candidate for phase 2 development for both neuropathic pain and depression.

    For more information, visit vistagen.com

    MissionIR provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.missionir.com

    Stocks: VTGN
Back To MissionIR's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.